Wanbury Limited Reports Strong FY26 Results with Profit More Than Doubling

Wanbury Limited's net profit for the fiscal year ended March 31, 2026, more than doubled to ₹66.13 crore from ₹30.53 crore in the previous year. Annual revenue grew to ₹650.27 crore.

Reader Takeaway: Strong profit growth and successful regulatory clearance contrast with one-time tax and liability adjustments.

What just happened

Wanbury Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported an annual revenue of ₹650.27 crore, an increase from ₹599.51 crore in FY25. Net profit after tax (PAT) saw substantial growth, reaching ₹66.13 crore compared to ₹30.53 crore in the prior year.

Why this matters

The significant increase in net profit, more than doubling year-on-year, is a key positive indicator for shareholders. The revenue growth demonstrates continued business expansion. While one-time exceptional items impacted profitability, the core operational performance appears robust.

The backstory

Wanbury Limited operates pharmaceutical manufacturing facilities, including USFDA-approved sites. The company has been focused on expanding its operational scale and regulatory compliance to cater to various international markets.

What changes now

Investors will note the substantial improvement in profitability. The one-time charge of ₹3.60 crore for gratuity and leave liabilities and the ₹5.52 crore write-off of deferred tax assets are non-recurring items. The successful MFDS-Korea inspection at the Patalganga facility strengthens its export potential.

Risks to watch

While the results are strong, investors should note the impact of exceptional items on the reported profit. The company's non-current borrowings stood at ₹147.15 crore as of March 31, 2026, requiring continued monitoring of debt management.

Peer comparison

Information on specific peers and their recent financial performance is not provided in the filing. A broader comparison would require analyzing the performance of other API and pharmaceutical formulation manufacturers in India.

Context metrics (time-bound)

• Annual Revenue (FY26): ₹650.27 crore
• Annual PAT (FY26): ₹66.13 crore
• Previous Year PAT (FY25): ₹30.53 crore
• Exceptional Items (FY26): ₹3.60 crore
• Deferred Tax Asset Write-off (FY26): ₹5.52 crore
• Non-current Borrowings (as of Mar 31, 2026): ₹147.15 crore

What to track next

Investors should monitor the company's performance in the upcoming quarters to assess the sustained impact of growth initiatives and the management of its debt obligations. The successful navigation of regulatory inspections remains crucial for export-oriented growth.